SCD and X-linked adrenoleukodystrophy: For example, it would be valuable to assess whether treatment with tissue- or isoform-specific LXR agonists [28], or other SCD1 modulators with reduced toxicity, can impact axonal degeneration in X-ALD without causing adverse side effects in the liver.